ColdControlRadio - Benutzerbeiträge [de]

GLP Closes First Sustainability-Linked Loan Of $658 Million, One Of The Largest In APAC

2026-08-13T13:52:04Z

ElbertBurchell: Die Seite wurde neu angelegt: „ Singapore, 22 February 2021 - GLP closed its first sustainability-linked loan (SLL) of US$658 million with participation from 10 banks. The loan is one of the largest SLLs in Asia Pacific and signifies GLP’s ongoing commitment to sustainability. GLP will use the loan proceeds to contribute to environmental objectives related to climate change mitigation and [http://www.tangjia7.com:8901/estellapritcha/1982229/wiki/Your+Friendly+Guide+to+GLP-1+Weigh…“

Singapore, 22 February 2021 - GLP closed its first sustainability-linked loan (SLL) of US$658 million with participation from 10 banks. The loan is one of the largest SLLs in Asia Pacific and signifies GLP’s ongoing commitment to sustainability. GLP will use the loan proceeds to contribute to environmental objectives related to climate change mitigation and [http://www.tangjia7.com:8901/estellapritcha/1982229/wiki/Your+Friendly+Guide+to+GLP-1+Weight+Loss%253A+what+Works%252C+what+Doesn%25E2%2580%2599t+and+What%25E2%2580%2599s+Next Medic GLP] the promotion of green buildings. The [https://venturebeat.com/?s=three-year%20revolving three-year revolving] credit facility was structured as a SLL tied to GLP’s latest Sustainalytics ESG Risk Rating. Under the facility, GLP is committed to improving its ESG Risk Rating score which reflects GLP’s performance in various ESG metrics. The SLL features a two-tier incentive mechanism where GLP will be entitled to an interest rate reduction when targeted improvements in its ESG performance score are achieved. Edwin Tey, Global Treasurer of GLP said: "The size of our first sustainability linked loan demonstrates how GLP has been able to capitalize on our achievements in sustainability and integrate ESG performance with financial metrics. ING acted as the lead sustainability structurer and coordinator for this deal and served as the sole advisor on GLP’s new green finance framework which will cover the company’s future green use-of-proceeds bond and loan issuances. GLP published its new Green Finance Framework which aligns with the four core components of the Green Bond Principles 2018, the Green Loan Principles 2020 and the ASEAN Green Bond Standards 2018. The new framework integrates sustainable development and action against climate change mitigation and is based on the company’s strategy and its ESG Policy. GLP’s Green Finance Framework has received a Second-Party Opinion from Sustainalytics. GLP and its strategic partners have raised more than US$1 billion in sustainability linked loans and green bonds globally. Notably, GLP J-REIT (TSE: 3281) has a SU1 (F) 1 rating (the highest possible rating) under the JCR Sustainability Finance Framework Evaluation and was the first logistics J-REIT to launch a green bond targeted at retail investors. In December 2020, GLP J-REIT issued 15-year sustainability bonds, the longest tenure for sustainability bonds in the J-REIT market. GLP is a leading global investment manager and business builder in logistics, real estate, infrastructure, finance and related technologies. Our combined investing and operating expertise allows us to create value for our customers and investors. We operate across Brazil, China, Europe, India, Japan, the U.S. Vietnam and have over US$100 billion in assets under [http://www.tangjia7.com:8901/estellapritcha weight management routine]. This press release is not an offer of securities for sale or a solicitation of an offer to purchase securities. The information in this press release may not contain, and you may not rely on this press release as providing, all material information concerning the condition (financial or other), earnings, business affairs, business prospects, properties or results of operations of GLP or its subsidiaries. This release may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements include statements regarding the intent, belief and current expectations of GLP or its officers with respect to various matters. When used in this press release, the words "expects," "believes," "anticipates," "plans," "may," "will," "should," "intends,""foresees," "estimates," "projects," and similar expressions, and the negatives thereof, are intended to identify forward-looking statements. Similarly, statements that describe objectives, plans or goals also are forward-looking statements. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, availability of real estate properties, competition from other companies and venues for the sale/distribution of goods and services, shifts in customer demands, customers and partners, changes in operating expenses, including employee wages, benefits and training, governmental and public policy changes, and the continued availability of financing in the amounts and the terms necessary to support future business. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the current view of management on future events and speak only as of the date of this press release. GLP does not undertake to revise forward-looking statements to reflect future events or circumstances. No assurance can be given that future events will occur, that projections will be achieved, or that GLP’s assumptions are correct.

GLP-1 Or Dual GIP/GLP-1 Receptor Agonists

2026-08-13T12:34:37Z

ElbertBurchell: Die Seite wurde neu angelegt: „ GLP-1 and dual GIP/GLP-1 receptor agonists are known to cause delayed gastric emptying, which may increase the risk of residual gastric contents despite preoperative fasting. GLP-1 or dual GIP/GLP-1 receptor agonists. Consider the possibility that patients may have purchased GLP-1 or dual GIP/GLP-1 receptor agonists for aesthetic [http://www.tangjia7.com:8901/estellapritcha MedicGLP Weight Management] loss and may not readily disclose this information…“

GLP-1 and dual GIP/GLP-1 receptor agonists are known to cause delayed gastric emptying, which may increase the risk of residual gastric contents despite preoperative fasting. GLP-1 or dual GIP/GLP-1 receptor agonists. Consider the possibility that patients may have purchased GLP-1 or dual GIP/GLP-1 receptor agonists for aesthetic [http://www.tangjia7.com:8901/estellapritcha MedicGLP Weight Management] loss and may not readily disclose this information unless directly asked. GLP-1 and dual GIP/GLP-1 receptor agonists are a class of medications that are used to treat type II diabetes mellitus and/or obesity. The GLP-1 and dual GIP/GLP-1 receptor agonists available in the UK include dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide. Tirzepatide is a GLP-1 receptor agonist combined with glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Semaglutide is also approved to reduce the risk of cardiovascular events in patients with established cardiovascular [https://sportsrants.com/?s=disease disease]. Some of the GLP-1 and dual GIP/GLP-1 receptor agonists have more than one brand name and more than one indication. Please refer to Annex 1 for the GLP-1 and dual GIP/GLP-1 receptor agonist products currently authorised in the UK with their brand names and indications. Residual gastric content is a risk factor for aspiration in patients who undergo surgery or procedures with general anaesthesia or deep sedation. All GLP-1 and dual GIP/GLP-1 receptor agonists slow down gastric emptying, therefore patients taking these medicines may have a higher risk of pulmonary aspiration due to retained gastric contents. This can potentially lead to severe complications, such as aspiration pneumonia. Cases have been reported in the literature as well as through Yellow Card reports. A recent European review of the available evidence for all GLP-1 and dual GIP/GLP-1 receptor agonists concluded that the data supports an association between GLP-1 or dual GIP/GLP-1 receptor agonists and the potential risk of pulmonary aspiration during anaesthesia or deep sedation because of the delayed gastric emptying associated with these medicines. The findings of this review were considered by the Pharmacovigilance Expert Advisory Committee (PEAG) of the Commission on Human Medicines (CHM), which agreed with the recommendations. The product information of all GLP-1 and dual GIP/GLP-1 receptor agonists has been updated to include the potential risk of pulmonary aspiration under general anaesthesia or deep sedation. The PEAG recommended that the MHRA inform healthcare professionals and patients of the possibility of aspiration in patients using GLP-1 or dual GIP/GLP-1 receptor agonists who undergo surgery or procedures requiring general anaesthesia or deep sedation. The European assessment evaluated whether a specific time to pause the use of a GLP-1 or dual GIP/GLP-1 receptor agonist prior to anaesthesia could be recommended, as well recommending new fasting guidelines or an appropriate medical procedure to confirm an empty stomach. The evidence to support further recommendations was limited and it was concluded that anaesthetists should retain the flexibility to provide individualised assessment. New warnings have been added to the Summaries of Product Characteristics (SmPC) and Patient Information Leaflets. The new advice aims to raise awareness of the risk of pulmonary aspiration amongst healthcare professionals and patients. Anaesthetists are warned that residual gastric contents may remain despite routine recommended fasting in patients taking a GLP-1 or dual GIP/GLP-1 receptor agonists. This should be considered within the preoperative risk assessment, with subsequent management in preventing or minimising the risk. As of 12 December 2024, the MHRA has received a very small number of reports of aspiration during a surgical procedure associated with GLP-1 or dual GIP/GLP-1 receptor agonists, including one case that resulted in aspiration pneumonia. In January 2025, the Association of Anaesthetists published a multidisciplinary consensus statement on ‘Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists (GLP-1). I am pleased to share the news that the UK Good Laboratory Practice Monitoring Authority's (UK GLPMA) guidance on the implementation and maintenance of a risk-based GLP quality assurance (QA) programme has been published. The GLPMA have for some time recognised there was a need to provide guidance to GLP facilities that would allow them to utilise modern quality risk assessment techniques in support of the conduct of GLP studies. This has become particularly apparent for those facilities engaged in activities that require compliance with other quality systems in addition to GLP, such as GMP and GCP. Having a risk-based GLP QA programme should offer facilities the flexibility to focus their resources in areas that present the biggest risk to their compliance status. During the last 13 years of inspecting I have been asked on many occasions how much is enough when it comes to QA. The answer to this question is not necessarily about the number of QA inspections conducted, it is about whether they add value in terms of assuring compliance. Also, are the inspections effective at identifying problems before they have a serious impact on the integrity of the data, compliance of the study or the facility as a whole? What’s right for one facility may not be right for another. The size of the facility, number of staff, amount of GLP work and the other quality systems in place are key factors in determining how much is enough. For [http://pcwang.vip:17608/cedricsexton1 MedicGLP Weight Support] example, the procedures for handling and dealing with deviations, amendments, errors, change etc. These systems can generate a lot of data - what does it tell you and how is it used? The challenge of course is to make sense of the data you have and turn it into meaningful information in order that you can make decisions as to how much QA is enough. Ultimately, the answer is to understand your processes and know where the risks are, then design your QA programme accordingly.

More Than 20 Per Cent Weight Loss: 'Breakthrough' Obesity Drug Trial

2026-08-13T11:21:44Z

ElbertBurchell: Die Seite wurde neu angelegt: „ US researchers are trumpeting a new drug as a "game changer" in the management of obesity - and for once, a large, gold-standard clinical trial backs up the hype. A single weekly injection of the drug semaglutide, for [http://www.tangjia7.com:8901/estellapritcha/1982229/wiki/Your+Friendly+Guide+to+GLP-1+Weight+Loss%253A+what+Works%252C+what+Doesn%25E2%2580%2599t+and+What%25E2%2580%2599s+Next MedicGLP] 68 weeks, saw an average loss of 15 percent body…“

US researchers are trumpeting a new drug as a "game changer" in the management of obesity - and for once, a large, gold-standard clinical trial backs up the hype. A single weekly injection of the drug semaglutide, for [http://www.tangjia7.com:8901/estellapritcha/1982229/wiki/Your+Friendly+Guide+to+GLP-1+Weight+Loss%253A+what+Works%252C+what+Doesn%25E2%2580%2599t+and+What%25E2%2580%2599s+Next MedicGLP] 68 weeks, saw an average loss of 15 percent body weight in trial participants. Those given a placebo, in tandem with a diet and exercise program, lost 2.4 per cent of their body weight. More than a third of the participants who took the drug lost more than 20 percent of their weight. As experts told the Times, these results far exceed the amount of weight loss observed in clinical trials of other obesity medications. The drug is a "game-changer," said Dr. Robert F. Kushner, an obesity researcher at Northwestern University Feinberg School of Medicine, who led the study. No long wait required. Semaglutide isn’t brand [http://orasch.com/index.php?title=GLP-1_Receptor_Agonists_(GLP-1RAs) MedicGLP] new. It was discovered in 2012 by researchers at Novo Nordisk, a Danish healthcare company with a focus on chronic disease. Novo Nordisk funded the latest trial. The drug was [https://www.bbc.co.uk/search/?q=approved approved] in 2017 by the USFDA as an injectable type II diabetes treatment. The New Daily has found that, [http://www.tangjia7.com:8901/estellapritcha MedicGLP Capsules] for the last four months, the drug has been prescribed off-label "for diabetic care and as a weight loss agent" by Western Australian bariatric surgeon, [http://pcwang.vip:17608/cedricsexton1 MedicGLP Dietary Supplement] Dr Leon Cohen. Dr Leon Cohen, surgeon and director of Mercy Bariatrics in WA has been prescribing the new weight-loss drug for about four months. Dr Cohen said his patients had been getting similar results to that achieved in the clinical trial - but at a much lower dose. "The drug usually comes with a starting dose of 0.25mg and then you gradually build it up to 1mg," he said. In the new trial, participants - who had a BMI of 30 or more, and thus technically obese - were given 2.4mg as an anti-obesity medicine. Dr Cohen said the drug mimics GLP-1, a gut hormone that’s released in response to undigested food hitting the distal small bowel. "It’s an interesting and exciting mechanism, because essentially what the body needs is a mechanism which can sense you’ve just had a large meal and there’s still a lot of undigested food that hasn’t been absorbed," he said. He said: "It doesn’t matter what treatment you give to someone with a low BMI, they get a good result. They only need to lose 10 kilos and you get a very respectable percentage of your weight loss. But most of his patients have a BMI over 40 and surgery remains their only viable option. Dr Cohen allowed that very few people who needed surgery could either afford it or were willing to take it up. It appears that for type II diabetics, or people edging into obesity, this new drug may be the game changer as touted by its makers. Side effects tend to be, in the main, mild gastrointestinal complaints. Long term effects at the higher dose are unknown. A1292) in the USA, Dr Cohen’s patients are charged $160 a month. He said for people with poorly controlled diabetes, with an authority script, the cost could be much lower. But once you’re on semaglutide, it’s probably for life. Trial participants rejoiced at their weight loss. But once they stopped taking the drug, the weight came back. Science continues to prove that the old adage "you are what you eat" is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your "gut microbiota." They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it? 1. Unable to lose weight and keep it off? 2. Struggling to fight cravings? 3. Sick of starving yourself for weight loss? 4. Baffled as to why no diet seems to really work for you? Depending on the composition of your gut microbiome, your microbes can either boost your health or weigh you down (figuratively and literally). The good news is this: You have control over these little guys with every bite you eat. Diet has the power to change the landscape of your gut microbiome. So, if you’ve tried multiple diets and can’t seem to get the results you want, it’s time to look into your gut microbiome.Will You Lose Weight Naturally on an Individualized Diet? If you’ve been struggling to lose weight and keep it off - it could be your gut microbiome. While Viome doesn’t guarantee weight loss, it has been an exciting result many of our customers have reported. "Fiona’s update day 37!

Benutzer:ElbertBurchell

2026-08-13T11:21:41Z

ElbertBurchell: Die Seite wurde neu angelegt: „I am Gregorio from Hiscott. I am learning to play the Xylophone. Other hobbies are Genealogy. Visit my web-site ... [http://www.tangjia7.com:8901/estellapritcha/1982229/wiki/Your+Friendly+Guide+to+GLP-1+Weight+Loss%253A+what+Works%252C+what+Doesn%25E2%2580%2599t+and+What%25E2%2580%2599s+Next MedicGLP]“

I am Gregorio from Hiscott. I am learning to play the Xylophone. Other hobbies are Genealogy. Visit my web-site ... [http://www.tangjia7.com:8901/estellapritcha/1982229/wiki/Your+Friendly+Guide+to+GLP-1+Weight+Loss%253A+what+Works%252C+what+Doesn%25E2%2580%2599t+and+What%25E2%2580%2599s+Next MedicGLP]